Trial · NCT05222555
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Tafasitamab Dose Level 1 + 25 mg Lenalidomide | 6 | Participants | ||
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Tafasitamab Dose Level 2 + 25 mg Lenalidomide | 45 | Participants | ||
| Number of Participants With Any ≥Grade 3 TEAE | Tafasitamab Dose Level 1 + 25 mg Lenalidomide | 5 | Participants | ||
| Number of Participants With Any ≥Grade 3 TEAE | Tafasitamab Dose Level 2 + 25 mg Lenalidomide | 38 | Participants | ||
| Ctrough of Tafasitamab After 3 and 12 Treatment Cycles | Tafasitamab Dose Level 1 + 25 mg Lenalidomide | Cycle 3 Day 15 | 170 | Standard Deviation 117 | micrograms per milliliter (μg/mL) |
| Ctrough of Tafasitamab After 3 and 12 Treatment Cycles | Tafasitamab Dose Level 2 + 25 mg Lenalidomide | Cycle 3 Day 15 | 228 | Standard Deviation 102 | micrograms per milliliter (μg/mL) |
| Ctrough of Tafasitamab After 3 and 12 Treatment Cycles | Tafasitamab Dose Level 1 + 25 mg Lenalidomide | Cycle 12 Day 28 | 87 | Standard Deviation 26 | micrograms per milliliter (μg/mL) |
| Ctrough of Tafasitamab After 3 and 12 Treatment Cycles | Tafasitamab Dose Level 2 + 25 mg Lenalidomide | Cycle 12 Day 28 | 149 | Standard Deviation 69 | micrograms per milliliter (μg/mL) |
| Cmax of Tafasitamab After 3 Treatment Cycles | Tafasitamab Dose Level 1 + 25 mg Lenalidomide | 792 | Standard Deviation 420 | micrograms per milliliter (μg/mL) | |
| Cmax of Tafasitamab After 3 Treatment Cycles | Tafasitamab Dose Level 2 + 25 mg Lenalidomide | 797 | Standard Deviation 273 | micrograms per milliliter (μg/mL) | |
| Best Objective Response Rate (ORR) by Investigator Assessment up to Treatment Cycle 12 | Tafasitamab Dose Level 1 + 25 mg Lenalidomide | 50.0 | 95% Confidence Interval 11.8 to 88.2 | percentage of participants | |
| Best Objective Response Rate (ORR) by Investigator Assessment up to Treatment Cycle 12 | Tafasitamab Dose Level 2 + 25 mg Lenalidomide | 48.9 | 95% Confidence Interval 34.1 to 63.9 | percentage of participants | |
| Number of Participants Developing Anti-tafasitamab Antibodies up to Treatment Cycle 12 | Tafasitamab Dose Level 1 + 25 mg Lenalidomide | 0 | Participants | ||
| Number of Participants Developing Anti-tafasitamab Antibodies up to Treatment Cycle 12 | Tafasitamab Dose Level 2 + 25 mg Lenalidomide | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05222555/results